logo
Twitter
Discord
Email
logo
Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc.

NASDAQ•VTYX
CEO: Dr. Sheila K. Gujrathi M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-10-21
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Contact Information
12790 El Camino Real, Suite 200, San Diego, CA, 92130, United States
760-593-4832
ventyxbio.com
Market Cap
$996.61M
P/E (TTM)
-9.3
38.2
Dividend Yield
--
52W High
$25.00
52W Low
$0.78
52W Range
54%
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.32-36.00%
4-Quarter Trend

FCF

-$17.56M-50.49%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Nine-month net loss narrowed to $77.3M USD, improving from $105.8M USD loss last period, reflecting better operational control.
R&D Spending Decreased Total R&D expenses for nine months fell $29.3M USD to $62.9M USD, primarily due to closeout of older development programs.
Operating Cash Burn Improved Cash used in operating activities decreased to $64.5M USD over nine months, showing better cash management compared to prior year.
VTX3232 Clinical Data Positive Reported positive topline results for VTX3232 in early-stage Parkinson's Phase 2a trial in June 2025 and obesity trial in October 2025.

Risk Factors

Future Financing Requirements High Substantial additional capital needed for development; failure to secure funding could delay or terminate critical product development efforts.
Clinical Trial Data Uncertainty Preliminary data may change materially upon audit; high attrition rate in clinical development remains a significant inherent risk factor.
VTX958 Internal Resource Reduction Will not commit significant internal resources to VTX958 development following Crohn's Phase 2 results, refining future strategy.
Stock Price Volatility Expected Stock price highly volatile based on clinical trial announcements and general market conditions; potential for significant investor loss.

Outlook

VTX2735 Phase 2 Results Due Anticipate interim topline results for VTX2735 Phase 2 trial in recurrent pericarditis during the fourth quarter of 2025.
Tamuzimod Partnering Exploration Intend to identify a partner or secure non-dilutive financing to support the pivotal Phase 3 program for tamuzimod in UC.
Cash Sufficient Twelve Months Current cash, equivalents, and marketable securities estimated sufficient to fund obligations for at least twelve months from report date.
Continue IP Protection Efforts Will continue efforts to obtain and enforce patent protection for product candidates against potential third-party infringement and maintain competitive edge.

Peer Comparison

Revenue (TTM)

Alector, Inc.ALEC
$69.05M
+12.3%
Inventiva S.A.IVA
$32.75M
+15.4%
Voyager Therapeutics, Inc.VYGR
$31.32M
-80.9%

Gross Margin (Latest Quarter)

Voyager Therapeutics, Inc.VYGR
100.0%
+0.0pp
Alector, Inc.ALEC
100.0%
+0.0pp
Humacyte, Inc.HUMA
65.5%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
VTYX$996.61M-9.3-48.1%4.7%
ANNX$725.94M-4.4-92.3%11.8%
ALLO$366.31M-1.7-57.8%19.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:-$0.41
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.32-36.0%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.38-15.6%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.39-37.1%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.97+40.3%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.50-45.7%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.45-50.5%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.62+1.6%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 27, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.30-60.2%
    N/A